Kynmobi

Generic name: apomorphine hydrochloride
Dosage form: sublingual film
Drug class:Dopaminergic antiparkinsonism agents

Medically reviewed by Judith Stewart, BPharm. Last updated on Feb 24, 2021.

What is Kynmobi?

Kynmobi is a prescription medicine used to treat short-term (acute), intermittent “off” episodes in people with Parkinson's disease (PD).

It is not known if this medicine is safe and effective in children.

Who should not take Kynmobi?

Do not take Kynmobi if you are:

• taking certain medicines to treat nausea called 5HT3 antagonists including ondansetron, granisetron, dolasetron, palonosetron, and alosetron.
• People taking ondansetron together with apomorphine, the active ingredient in Kynmobi, have had very low blood pressure and lost consciousness or “blacked out.”
• allergic to apomorphine hydrochloride or to any of the other ingredients. See the end of the page for a complete list of ingredients.
• Kynmobi also contains a sulfite called sodium metabisulfite. Sulfites can cause severe, life-threatening allergic reactions in some people. An allergy to sulfites is not the same as an allergy to sulfa. People with asthma are more likely to be allergic to sulfites.
  Call your healthcare provider or get emergency help right away if you get any of the following symptoms of a severe life-threatening allergic reaction:
  
  • hives
  • itching
  • rash
  • swelling of the lips, tongue, and mouth
  • redness of your face (flushing)
  • throat tightness
  • trouble breathing or swallowing

Before taking Kynmobi

Before you start treatment, tell your healthcare provider about all of your medical conditions, including if you:

• have difficulty staying awake during the daytime.
• have dizziness.
• have fainting spells.
• have low blood pressure.
• have asthma.
• are allergic to any medicines containing sulfi..